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Targeted busulfan (TBU) and cyclophosphamide (CY) for allogeneic hematopoietic cell transplantation carries
a high risk of sinusoidal obstruction syndrome (SOS) in patients undergoing transplantation for myeloﬁbrosis.
We tested the hypothesis that reversing the sequence of administration (from TBU/CY to CY/TBU) would
reduce SOS and day þ100 nonrelapse mortality. We enrolled 51 patients with myeloﬁbrosis (n ¼ 20), acute
myelogenous leukemia (n ¼ 20), or myelodysplastic syndrome (n ¼ 11) in a prospective trial of CY/TBU
conditioning for allogeneic hematopoietic cell transplantation. CY 60 mg/kg/day i.v. for 2 days was followed
by daily i.v. BU for 4 days, targeted to a concentration at steady state (Css) of 800-900 ng/mL. Compared with
TBU/CY-conditioned patients, CY/TBU-conditioned patients had greater exposure to CY (P < .0001) and less
exposure to 4-hydroxycyclophosphamide (P < .0001). Clinical outcomes were compared between cases and
controls (n ¼ 271) conditioned with TBU/CY for the same indications. In patients with myeloﬁbrosis, CY/TBU
conditioning was associated with a signiﬁcantly reduced incidence of SOS (0% versus 30% after TBU/CY; P ¼
.006), whereas the incidence of SOS was low in both cohorts with acute myelogenous leukemia/myelodys-
plastic syndrome. Day þ100 mortality was signiﬁcantly lower in the CY/TBU cohort (2% versus 13%; P ¼ .01).
CY/TBU conditioning had a marked affect on the pharmacokinetics of CY and was associated with signiﬁcantly
lower incidence of SOS and day þ100 mortality, suggesting that CY/TBU is superior to TBU/CY as conditioning
for patients with myeloﬁbrosis.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Busulfan (BU) followed by cyclophosphamide (CY) is
a commonly used high-dose conditioning regimen in allo-
geneic hematopoietic cell transplantation (HCT). Regimen-
related toxicity, graft rejection, and relapse in patients
conditioned with BU/CY have been reduced by individual-
ized dosing of BU to a target steady-state concentration
(targeted BU [TBU]) [1,2]. However, neither BU dose targeting
nor the introduction of i.v. TBU has eliminated hepatic sinu-
soidal obstruction syndrome (SOS) as a cause of morbidity
and mortality [3,4]. BU is not inherently toxic to hepatocytes
or to sinusoidal endothelial cells, whereas metabolites of CY,
generated within hepatocytes and transported into hepatic
sinusoids, are highly toxic to sinusoidal endothelial cells
[5-7]. It follows that CY metabolites are the prime cause of
regimen-related liver toxicity following administration of
the TBU/CY regimen.
There are several possible approaches to minimizing
regimen-related toxicity caused by the combination of TBU
and CY. One approach is to eliminate CY altogether by, for
example, using a regimen of ﬂudarabine and TBU [8,9]. A
second approach involves eliminating variability of CY expo-
sure with pharmacokinetic targeting of CY doses, which isual meeting of the American Society of
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13.04.005feasible and effective in reducing toxicity [10]. A third, simpler
approach is to reverse the order of administration, giving CY
ﬁrst, followed by i.v. TBU (CY/TBU). The pharmacologic ratio-
nale for a CY/TBU regimen rests on the following observations:
(1) BU depletes hepatic glutathione and at high concentra-
tions induces oxidative stress in murine hepatocytes in vitro
[6]; (2) glutathione is important in both the detoxiﬁcation
of the CY metabolite 4-hydroxycyclophosphamide (HCY)
through conversion to glutathionyl-CY and in the elimination
of the toxic CY metabolite acrolein [5,11]; (3) restoration of
hepatic and sinusoidal endothelial cell glutathione levels
prevents injury tohepatic sinusoids in several different animal
models of toxic liver injury [12]; and (4) studies in patients
receiving high-dose conditioning regimens have suggested
a reduced risk of hepatotoxicity when BU is given after, rather
than before, other conditioning agents [13-15]. Thus, giving
BU ﬁrst appears to potentiate CY toxicity, providing the basis
for administering these drugs in reverse order (CY/TBU) to
reduce toxicity.
Here we report the results of a prospective clinical trial
designed to test the hypothesis that reversed-sequence
(CY/TBU) conditioning reduces the frequency and severity
of hepatotoxicity compared with the standard sequence of
BU followed by CY (TBU/CY). In addition, we collected phar-
macokinetic data to test whether altering the sequence of
conditioning agents led to measurable changes in CY
metabolism and exposure to CY metabolites. We enrolled 2
cohorts of patients, 1 cohort at high risk for toxic sinusoidal
liver injury (patients with myeloﬁbrosis) [16] and the other
at standard risk (patients with myelodysplastic syndromeTransplantation.
Table 1
Conditioning Regimens for Cases (CY/TBU) and Controls (TBU/CY)
CY/TBU Cases
(n ¼ 51)
TBU/CY Controls
(n ¼ 271)
Conditioning agents, by transplantation day
7 CY i.v. 60 mg/kg* BUy
6 CY i.v. 60 mg/kg TBU
5 BUc TBU
4 TBU TBU
3 TBU CY i.v. 60 mg/kg*
2 TBU CY i.v. 60 mg/kg
1 Rest Rest
0 Allograft infusion Allograft infusion
BU administration route and dosing frequency, n (%)
Oral every 6 h 0 252 (93)
i.v. every 6 h 0 15 (6)
i.v. once daily 51 (100) 4 (1)
Cumulative BU dose, mg,
median (range)
Oral Not applicable 1048 (572-1916)
i.v. 1098 (580-1510) 976 (608-1668)
Target BU Css, ng/mL, n (%)
900z 0 2 (0.7)
600-900 0 3 (1.1)
800-900 51 (100) 262 (96.7)
>900z 0 4 (1.5)
BU pharmacokinetics
First dose Css >900 ng/mL,
n (%)
23 (45) 128 (47)
Average daily Css >900 ng/mL,
n (%)x
1 (2) 18 (7)
Average daily Css, ng/mL,
median (range)x
856 (811-1191) 861 (627-968)
BU indicates busulfan; TBU, targeted busulfan; CY, cyclophosphamide; Css,
steady-state concentration.
* 2-Mercaptoethane sulfonate was given concurrently with i.v. CY to
prevent hemorrhagic cystitis.
y Phenytoin was started 1 day before TBU and continued throughout TBU
administration (ie, day 6 through day 1 for CY/TBU and day 8 through
day 3 for TBU/CY).
z Speciﬁc target Css detailed in the text.
x Cumulative over all 4 days of TBU administration. For Css, each patient’s
TBU Css over all 4 days was calculated, and then divided by 4 to provide the
average daily Css.
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liver toxicity and outcomes with those in concurrent and
historical control patients who received TBU/CY and alloge-
neic HCT for the same disease indications. The primary
outcome was the incidence of moderate/severe SOS after
allogeneic HCT.
MATERIALS AND METHODS
Patient Selection
Study patients (cases) were enrolled from March 1, 2007, through June
30, 2010, on FredHutchinson Cancer Research Center (FHCRC) Protocol 2130.
This protocol was approved by the FHCRC Institutional Review Board and
registered at www.clinicaltrials.gov as NCT00445744. All patients provided
written informed consent using forms approved by the Institutional Review
Board. Under the aegis of Institutional ReviewBoardeapproved Protocol 881,
a cohort of historical patients (controls) was obtained by retrieving clinical
data on consecutive patients with myeloﬁbrosis, AML, or MDS undergoing
allogeneic HCT after TBU/CY conditioning between January 1, 2003, and
December 31, 2009.
Eligibility Criteria
Eligibility criteria included (1) presence of primary myeloﬁbrosis, myelo-
ﬁbrosis secondary to polycythemia vera or essential thrombocythemia, AML,
orMDS; (2) age<61 years if receiving a transplant from an unrelated donor or
age <66 years if receiving a transplant from a related donor; (3) receipt of
unmanipulated granulocyte colony stimulating factoremobilized peripheral
blood mononuclear cells (G-PBMCs) or granulocyte colony stimulating
factorestimulated bone marrow allograft products; (4) Karnofsky perfor-
mance status of >70% at the time of HCT; and (5) ability to provide informed
consent. Patients were required to have an HLA-identical related donor or an
HLA-matched or 1 HLA alleleemismatched unrelated donor identiﬁed before
enrollment.
Exclusion criteria included (1) HIV infection or active viral hepatitis; (2)
use of medications known to strongly inhibit the cytochrome P450 pathway
that could not be safely discontinued during conditioning, in the judgment
of the attending physician; (3) known hypersensitivity to BU or CY; (4)
hepatic dysfunction, as evidenced by total serum bilirubin or aspartate
aminotransferase more than 2 times the upper limit of normal, or evidence
of synthetic dysfunction or cirrhosis; (5) renal insufﬁciency, as evidenced by
creatinine clearance <50% of expected, serum creatinine more than 2 times
the upper limit of normal, or dialysis dependence; (6) impaired pulmonary
function, as evidenced by arterial partial pressure of oxygen (PaO2) <70 mm
Hg and diffusing capacity of the lung for carbon monoxide (DLCO) <70% of
predicted or by PaO2 <80 mm Hg and DLCO <60%, or requirement for
continuous supplementary oxygen; and (7) impaired cardiac function, as
evidenced by an ejection fraction <35% or the presence of symptomatic
coronary artery disease.
Conditioning Regimen
The conditioning regimens for protocol cases and control patients are
summarized in Table 1. All patients were conditioned with CY 60 mg/kg/day
i.v. for 2 consecutive days (total dose, 120 mg/kg) and targeted BU, given
for 4 consecutive days. On the days of CY infusion, patients received
2-mercaptoethane sulfonate at milligram doses equal to those of CY as
prophylaxis against uroepithelial damage.
Cases (n ¼ 51) received CY followed by TBU (CY/TBU). CY was adminis-
tered i.v. at 60 mg/kg/day on days 7 and 6 before HCT. TBU was admin-
istered i.v. as Busulfex (Otsuka Pharmaceutical, Tokyo, Japan) once daily on
days 5 through 2, for a total of 4 daily doses. Prophylactic phenytoin was
initiated on day6 after completion of the second CY dose and discontinued
on day 1. One patient received prophylactic levetiracetam.
Patients in the control cohort (n ¼ 271) received TBU followed by CY
(TBU/CY). In this cohort, BU was administered orally on days 7 through 4
at an initial dose of 1 mg/kg every 6 hours in 252 patients (93%), i.v. at
a starting dose of 0.8 mg/kg every 6 hours in 15 patients (6%), and i.v. at
a starting dose of 3.2 mg/kg daily in 4 patients (1%). After the initial weight-
based dose of BU, subsequent doses were adjusted to achieve the target
plasma steady-state concentrations (Css) shown in Table 1. CY was admin-
istered at 60 mg/kg/day i.v. on days 3 and 2. Prophylactic phenytoin was
given from day 8 through day 3.
CY Dosing and Pharmacokinetics
CYwas infused through a central venous catheter. The CY dosewas based
on adjusted ideal body weight (0.25 [actual weight ideal weight]þ ideal
weight) if actual body weight was greater than ideal body weight [17]. The
infusion duration followed FHCRC Standard Practice Guidelines; total CY
doses of <5000 mg were infused over 1 hour, and doses 5000 mg wereinfused over 2 hours. The CY dose was not adjusted based on pharmacoki-
netic data.
In cases (CY/TBU) only, blood samples were drawn after each dose of CY
from the central venous line at 2, 4, 8, 16, 20, and 24 hours after the start of
CY infusion and at the cessation of CY infusion. If the CY infusion lasted
1.5 hours or longer, then blood samples were instead drawn at 3, 5, 8, 16, 20,
and 24 hours after the start of CY infusion and at the cessation of CY infusion.
At each of these time points, blood was aliquoted into 2 tubes, 1 tube con-
taining EDTA for analysis of CY and carboxyethylphosphoramide mustard
(CEPM) and the other containing phenylhydrazine HCl to stabilize HCY, as
described previously [18]. Samples were refrigerated at the bedside at
a target temperature of 4 C until being transported (within 12 hours) to the
pharmacokinetics laboratory. Plasma concentrations of CY, HCY, and CEPM
were quantiﬁed by liquid chromatography mass spectroscopy methods [10].
A patient’s exposure to CYand itsmetaboliteswas calculated by determining
the area under the curve (AUC) for CY (AUCCY), for HCY (AUCHCY), and for
CEPM (AUCCEPM) for interval from 0 to 48 hours using noncompartmental
analysis. These AUCs were compared with those previously reported in
patients receiving TBU/CY [18]. CY pharmacokinetics were not evaluated in
the historical control patients.
BU Dosing and Pharmacokinetics
In the 51 cases (CY/TBU), daily i.v. BU doses were standardized in terms
of time of administration, duration of infusion, and administration of saline
ﬂushes in the i.v. line, to ensure consistent BU pharmacokinetics. In these
patients, the ﬁrst BU dose (day 5) was 4 mg/kg, with body weight calcu-
lated as described above [17]. All subsequent BU doses were adjusted to
achieve a Css of 800-900 ng/mL.
In the 271 control patients (TBU/CY), the BU administration route and
target Css were chosen by the attending physician. The majority of patients
received oral BU every 6 hours (n ¼ 252); a minority received i.v. BU every
Table 2
Patient Characteristics
Characteristic CY/TBU Cases
(n ¼ 51)
TBU/CY Controls
(n ¼ 271)
Age, years, median (range) 55 (30-65) 50 (19-67)
Diagnosis, n (%)
Acute myelogenous leukemia 20 (39) 143 (53)
Myelodysplasia 11 (22) 95 (35)
Myeloﬁbrosis 20 (39) 33 (12)
Donor, n (%)
Related 28 (55) 96 (35)
Unrelated 23 (45) 175 (65)
HLA-matched 21 98
One HLA allele-mismatched 2 77
Allograft source, n (%)
G-PBMCs 51 (100) 223 (83)
Bone marrow 0 (0) 48 (17)
CD34þ dose, cells/kg recipient
weight, median (range)
13.4 (6.8-28.5) 9.1 (0.5-45.0)
Kahl disease risk, n (%)*
Low/moderate 30 (59) 196 (72)
High 21 (41) 75 (28)
CY indicates cyclophosphamide; TBU, targeted busulfan; G-PBMCs, gran-
ulocyte colony-stimulating factor-mobilized peripheral blood mononuclear
cells.
* Kahl disease risk reﬂects the risk of relapse after allogeneic hemato-
poietic cell transplantation [21].
Table 3
Comparison of Pharmacokinetics of CY, HCY, and CEPM by Conditioning
Regimen
CY/TBU TBU/CY [18] P Value
CY
Peak [CY], day 1 375  60 312  171 <.0001
Peak [CY], day 2 329  66 283  124 <.0001
AUCCY 4899  1255 2563  1190 <.0001
HCY
Peak [HCY], day 1 9  5 35  18 <.0001
Peak [HCY], day 2 20  9 36  13 <.0001
AUCHCY 168  48 290  98 <.0001
CEPM
Peak [CEPM], day 1 12  6 27  12 <.0001
Peak [CEPM], day 2 26  11 32  29 .25
AUCCEPM 475  180 522  194 .14
CY indicates cyclophosphamide; TBU, targeted busulfan; AUC, area under the
curve; HCY, 4-hydroxycyclophosphamide; CEPM, carboxyethylphosphor-
amide mustard. Peak concentrations (mM) are the highest concentrations
recorded on that day. AUC (mM$h) is from time 0 to 48 hours. Comparisons
are adjusted for age.
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most patients (n¼ 262) was 800-900 ng/mL; 5 patients had target Css900
ng/mL, and 4 patients had a target Css >900 ng/mL.
In both cases and controls, blood samples for BU pharmacokinetics
(3 mL/sample) were collected in sodium heparinecontaining tubes at the
time points described previously [8]. Samples were stored on wet ice or
refrigerated until being transported to the laboratory, where plasma BU
concentrations were analyzed by gas chromatography with mass selective
detection as described previously [19]. The dynamic range was 62-4500
ng/mL, and the intraday and interday coefﬁcients of variationwere <5% and
<8%, respectively.
Individual patient concentration-time data were ﬁt using WinNonlin
version 5.2 (Pharsight, Sunnyvale, CA). The AUC from time 0 to inﬁnity (AUC0
toN) was calculated after each dose. Clearance and Css were calculated based
on the following equations:
Clearance ¼ doseOAUC
Css ¼ AUC0 to  BU molecular weight ð246:3 g=molÞOdosing interval:
After calculation of each patient’s clearance, subsequent dose levelswere
calculated linearly to achieve the target Css, as described previously [17].
Supportive Care and Prophylaxis
Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus
and methotrexate. Tacrolimus was given as a continuous i.v. infusion
beginning on day 1 at an initial dose of 0.03 mg/kg/day, with doses
adjusted to achieve a trough tacrolimus Css of 5-15 ng/mL. Tacrolimus
admininstration was changed from i.v. infusion to divided oral dosing as
soon as could be tolerated. In the absence of GVHD, tacrolimus was tapered
in 20% decrements starting on day þ56 after HCT and discontinued
completely by dayþ200. In patients with GVHD, tacrolimus was maintained
at therapeutic trough concentrations, with subsequent tapering and
management dictated by the attending transplantation physician on the
basis of clinical GVHD activity. Methotrexate was given at a dose of 10 mg/
m2 i.v. on day þ1 (at least 24 hours after donor cell infusion) and on
days þ3, þ6, and þ11.
All patients received antifungal, antiviral, and antibacterial prophylaxis
in accordance with standard practice at FHCRC. Hematopoietic growth
factors were given only in the event of prolonged neutropenia after dayþ21.
Ursodiol was administered orally to both cases and historical controls at 12
mg/kg/day, starting 2 weeks before the initiation of conditioning, again in
accordance with FHCRC standard practice.
Evaluation of Outcomes
All case and control patients were evaluated by 2 investigators (G.B.M.
andA.K.) for evidence of SOS afterHCT. The diagnosis of SOSwas based on the
presence of at least 2 of the following features by day þ20 after HCT:
hyperbilirubinemia (ie, serum bilirubin >2.0 mg/dL), hepatomegaly or right
upper quadrant pain of liver origin, andweight gain (>2%of dry bodyweight)
due to ﬂuid accumulation [20]. Patients with other possible causes of liver
dysfunction (eg, GVHD, sepsis syndrome, drug-induced liver injury) were
classiﬁed as having liver disease of uncertain etiology. The severity of SOS
was graded as mild (resolving without speciﬁc treatment), moderate
(requiring diuretics, sodium restriction, or analgesics, but with eventual
resolution of abnormalities), or severe (death or nonresolution by dayþ100).
Overall survival was estimated by the Kaplan-Meier method. The
cumulative incidences of nonrelapse mortality (NRM) and relapse were
estimated by standard methods, treating these outcomes as mutually
competing events. Statistical comparisons of survival, NRM, and relapse
between groups used Cox regression, restricting the analysis to events
within the ﬁrst 100 days or ﬁrst 2 years after HCT, as indicated. The asso-
ciations of AUCCYand its metabolites with these outcomes were evaluated as
a test for trend over quartiles using Cox regression. Statistical comparisons
of the frequency of SOS were done using the chi-squared test. Pharmaco-
kinetic parameters were compared between regimens using the Wilcoxon
rank-sum test. Comparisons of relapse rates were adjusted using the disease
risk criteria described by Kahl et al. [21]. Outcomes in patients with AML/
MDS were compared with those in patients with myeloﬁbrosis as part of
a prespeciﬁed subset analysis.
RESULTS
Patient Characteristics
Patient and disease characteristics are summarized in
Table 2. Themedian age of cases was 55 years (range, 30 to 65
years). Twenty case patients (39%) had myeloﬁbrosis, 11
(22%) had MDS, and 20 (39%) had AML. Two patients hadundergone previous allogeneic HCT; 1 patient, with myelo-
ﬁbrosis, had rejected an allograft after TBU/CY conditioning
10 years earlier, and the other, with AML, had relapsed
after HCT with reduced-intensity conditioning performed
3 months before study enrollment. The median age in the
control cohort of 271 patients was 50 years (range, 19 to 67
years). In the control cohort, 33 patients (12%) had myeloﬁ-
brosis, 143 (53%) had AML, and 95 (35%) had MDS.Cyclophosphamide Pharmacokinetics
Peak plasma concentrations and AUCCY, AUCHCY, and
AUCCEPM are summarized in Table 3 and Figure 1. The
patients receiving CY/TBU showed considerable variability in
exposure to CY metabolites, including a 3.7-fold variation in
AUCCY, a 3.6-fold variation in AUCHCY, and a 4.8-fold variation
in AUCCEPM. Pharmacokinetic parameters for patients
receiving CY/TBU were compared with those obtained
previously for 75 patients who received TBU/CY conditioning
[18]. These analyses were adjusted for patient age, given the
Figure 1. Comparison of CY, HCY, and CEPM exposure by conditioning
regimen. AUC0-48hr in patients receiving CY/TBU (gray) and TBU/CY (white).
Boxes designate 25th, 50th, and 75th percentiles; whiskers designate 5th and
95th percentiles.
Table 4
Relationship between Exposure to CY and Its Metabolites and Clinical
Outcomes among Cases Conditioned with CY/TBU*
Clinical Outcome ny Pharmacokinetic Parameters,
HR (P Value)
AUCCY AUCHCY AUCCEPM
Nonrelapse mortality 10 1.15 (.64) 1.67 (.11) 1.40 (.25)
Relapse 9 1.05 (.84) 1.2 (.53) 1.53 (.10)
Overall mortality 20 1.28 (.26) 1.74 (.03) 1.67 (.02)
CY indicates cyclophosphamide; TBU, targeted busulfan; HR, hazard ratio;
AUC, area under the curve; HCY, 4-hydroxycyclophosphamide; CEPM, car-
boxyethylphosphoramide mustard.
* AUC is modeled as a continuous linear variable, with HRs for AUCCEPM
and AUCHCY representing an increase in HR associated with an increase in
AUC of 100 mM$h. HRs for AUCCY represent an increase in hazard associated
with increase in AUC of 1000 mM$h. HRs are adjusted for age at time of HCT,
type of donor, and relapse risk.
y Number of events in cohort in 51 cases.
Table 5
Incidence of Sinusoidal Obstruction Syndrome and Liver Disease of
Unknown Etiology in Patients Conditioned with TBU/CY Versus CY/TBU
CY/TBU (n ¼ 51) TBU/CY (n ¼ 271)
Myeloﬁbrosis, n (%) 20 33
No liver disease 17 (85) 19 (58)
LDUE 3 (15) 4 (12)
SOS 0 (0) 10 (30)
Mild 0 2
Moderate 0 6
Severe 0 2
AML/MDS, n (%) 31 238
No liver disease 26 (84) 203 (85)
LDUE 3 (10) 13 (5)
SOS 2 (6) 22 (9)
Mild 0 3
Moderate 2 10
Severe 0 9
CY indicates cyclophosphamide; TBU, targeted busulfan; LDUE, liver disease
of unknown etiology; SOS, sinusoidal obstruction syndrome; AML, acute
myelogenous leukemia; MDS, myelodysplastic syndrome.
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patient agewas 55 years (range, 30 to 65 years) in the CY/TBU
cohort and 44 years (range, 20 to 66 years) in the historical
TBU/CY cohort [18].
The sequence of CY/TBU administration had a marked
affect on CY pharmacokinetics (Table 3 and Figure 1). When
CY was given ﬁrst (CY/TBU), there was a signiﬁcant increase
in AUCCY (4899 versus 2563 mU$h; P < .0001) and a signiﬁ-
cant decrease in AUCHCY (168 versus 290 mU$h; P < .0001)
compared with values seenwith standard TBU/CY. There was
also a trend toward lower AUCCEPM with CY/TBU (475 versus
522 mU$h, P ¼ .14). In the CY/TBU cohort, there were no
apparent differences in BU Css or in the AUC of CY and its
metabolites between patients with myeloﬁbrosis and those
with AML/MDS (data not shown). In the CY/TBU cohort,
associations of AUCCY, AUCHCY, and AUCCEPM with SOS could
not be evaluated statistically, because only 2 cases of SOS
occurred. Relapse and NRM were not associated with AUCCY,
AUCHCY, and AUCCEPM; however, higher AUCHCY and AUCCEPM
were associatedwith inferior overall survival (P¼ .03 and .02,
respectively) (Table 4).
Clinical Outcomes in Cases
All patients in the CY/TBU cohort initially engrafted
(deﬁned as a rise in absolute neutrophil count to>500 cells/mL
for at least 3 consecutive days) at a median of 17 days (range,
11 to 30 days) after HCT. One patient with AML/MDS who
received an HLA alleleemismatched allograft from an unre-
lated donor suffered late graft failure at 3 months after HCT.
Approximately one half of cases (26 of 51; 51%) did not
require parenteral nutrition within the ﬁrst 20 days after
allogeneic HCT. In patients with myeloﬁbrosis, the median
peak serum total bilirubin level through day þ20 was 2.3 mg/
dL (range, 0.7 to 30.0 mg/dL). In patients with AML/MDS, the
median peak serum total bilirubin level through day þ20 was
1.1 mg/dL (range, 0.5 to 12.4 mg/dL). The incidence of SOS was
0 of 20 (0%) in patients withmyeloﬁbrosis and 2 of 31 (6.5%) in
patients with AML/MDS (Table 5). No patient in the CY/TBU
cohort developed severe SOS.
Acute GVHD grade II-IV and grade III-IV occurred in 67%
and 8% of cases, respectively, at a median of 28 days (range,8 to 102 days) after HCT. Chronic GVHD developed in 41%
of cases, at a median of 189 days (range, 92 to 530 days)
after HCT.
The median follow-up of surviving cases was 19 months,
and 32 patients (63%) were alive at last follow-up. Day þ100
mortality was 0% in patients with myeloﬁbrosis and 3% in
those with AML/MDS. At 2 years after HCT, cumulative inci-
dence estimates for overall survival were 68% in patients
with myeloﬁbrosis and 56% in those with AML/MDS, and
cumulative incidence estimates for NRM were 27% in
patients with myeloﬁbrosis and 17% in those with AML/MDS.
The cumulative incidence of relapse was 11% in patients with
myeloﬁbrosis and 44% in patients with AML/MDS.
The major causes of death were relapsed malignancy
in patients with AML/MDS and GVHD (with or without
concomitant infection) in patients with myeloﬁbrosis. One
patient withmyeloﬁbrosis died of metastatic prostate cancer,
which was diagnosed approximately 6 months after HCT.
One patient with AML/MDS committed suicide at day þ102
after HCT.
Comparison of Outcomes after CY/TBU versus TBU/CY
Among patients with myeloﬁbrosis, CY/TBU conditioning
was associated with a signiﬁcantly reduced incidence of SOS
compared with TBU/CY conditioning (0% versus 30%; P ¼
.006). In patients with AML/MDS, the SOS rate was 6.5% with
CY/TBU and 9.2% with TBU/CY (P ¼ .61). There were no cases
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in the TBU/CY cohort.
In patients with myeloﬁbrosis, median peak serum total
bilirubin levels through day þ20 did not differ signiﬁcantly
by conditioning agent sequence (2.3 mg/dL in the CY/TBU
group versus 2.2 mg/dL in the TBU/CY group; P ¼ .95). In
patients with AML/MDS, the CY/TBU group showed a trend
toward a lower median peak serum total bilirubin level
through day þ20 (1.1 mg/dL versus 1.4 mg/dL; P ¼ .07).
Patients conditioned with CY/TBU had signiﬁcantly lower
day þ100 mortality compared with those conditioned with
TBU/CY (2% versus 12%; P ¼ .01). For patients with myeloﬁ-
brosis, the 2-year cumulative incidence of relapse was 11% in
the CY/TBU group and 6% in the TBU/CYgroup (P¼ .62). There
were no signiﬁcant between-group differences in the 2-year
cumulative incidence of NRM (27% versus 25%; P ¼ .91) or
overall survival (68% versus 72%; P ¼ .78) (Figure 2).
For patients with AML/MDS, the 2-year cumulative inci-
dence of relapse was 44% with CY/TBU versus 20% with
TBU/CY (P ¼ .008); the 2-year cumulative incidence of NRM
was 17% versus 22% (P ¼ .84), and the 2-year cumulative
incidence of overall survival was 56% versus 64% (P ¼ .57)
(Figure 3). The higher incidence of relapse in patients with
AML/MDS conditioned with CY/TBU remained statistically
signiﬁcant, albeit attenuated, after adjustment for the greater
disease risk in this cohort (unadjusted hazard ratio [HR], 2.57,
P ¼ .008; adjusted HR, 2.15, P ¼ .02).
DISCUSSION
The major ﬁndings of this study are as follows: (1) Daily
i.v. BU can be safely administered after high-dose CY; (2) the
sequence of BU and CY administration has a signiﬁcant effect
on CY metabolism; and (3) compared with the standard
sequence of TBU/CY, CY/TBU conditioning is associated with
a signiﬁcantly reduced risk of day þ100 mortality, a signiﬁ-
cantly lower incidence of SOS, and the absence of severe SOS.
In patients with myeloﬁbrosis, the decrease in SOS incidence
from 30% to 0% with a simple reversal of conditioning agentFigure 2. Overall survival, NRM, and relapse in patients with myeloﬁbrosis conditisequence is both statistically and clinically signiﬁcant. BU is
not inherently hepatotoxic as a single agent in vitro or in
human overdoses [6,23]. Our data reinforce the idea that
regimen-related liver damage results largely from toxic
metabolites of CY, although we recognize reports of hepa-
totoxicity attributed to BU in combination with ﬂudarabine
as well [24,25].
Recent reports support the safety of daily i.v. BU with CY
[26,27]. However,Williams et al. [28] concluded that daily i.v.
BU at 3.2 mg/kg/day for 4 days followed by CY 60 mg/kg/day
for 2 days resulted in excessive toxicity; autopsy-conﬁrmed
SOS occurred in 2 of their 3 patients who received this
regimen, with a BU Css of >1025 ng/mL. Our cases received
the same dose of CY, but in the reverse sequence, followed by
daily i.v. BU at a higher initial dose of 4 mg/kg, with subse-
quent BU doses targeted to a Css of 800-900 ng/mL. This
target BU Css range is well below the BU Css ranges of 925 to
1025 ng/mL previously associated with elevated SOS rates in
adults conditioned with BU/CY [2,29,30]. Our data demon-
strate acceptable toxicity when CY is administered before
daily i.v. TBU at an initial BU dose of 4 mg/kg. Notably, the
clearance of daily i.v. BU did not change during days5 to3
in patients receiving CY/TBU [17]. Nevertheless, even in
patients receiving CY/TBU, CY metabolism showed substan-
tial interpatient variability when the CY dose, phenytoin
dose, and BU Css were held constant among patients (Table 3
and Figure 1).
Patients receivingCY/TBUhadgreaterexposure toCY, lower
exposure to HCY, and similar exposure to CEPM compared
with TBU/CY-conditioned patients. These data agree with our
previous report comparing CY/total body irradiation (ie, CY
ﬁrst) and TBU/CY (ie, CY after BU/phenytoin) [18]. The use of
phenytoin as a prophylactic antiepileptic may contribute to
this difference. We sought to characterize the clinical signiﬁ-
cance of the variability in CY pharmacokinetics (Table 4).
Theoretically, reduced HCY exposure may translate into less
immunosuppressive effect, although AUCHCY was not as-
sociated with clinical outcomes in patients conditioned withoned with CY/TBU (n ¼ 20) versus those conditioned with TBU/CY (n ¼ 33).
Figure 3. Overall survival, NRM, and relapse in patients with AML/MDS conditioned with CY/TBU (n ¼ 31) versus those conditioned with TBU/CY (n ¼ 238).
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we previously described AUCCEPM as a reporter for liver
toxicity, with a strong correlation with sinusoidal hepatotox-
icity and mortality [7,22]. We could not perform a pharmaco-
dynamic analysis of SOSwithCYmetabolites, because only 2 of
the CY/TBU cases developed SOS. We found statistically
signiﬁcant relationships between overall survival and AUCHCY
and AUCCEPM (Table 4).
Altering the sequence of conditioning agents is an
appealingly simple and inexpensive strategy that uses readily
available and familiar medications. Following preclinical
studies [5,31,32], this approach has been translated into clin-
ical trials in humans. Kerbauy et al. [14] evaluated the use of
CY/BU conditioning in a cohort of 11 patients and reported
lower peak serum aminotransferase levels compared with
BU/CY-conditioned historical controls [14]. Of note, peak
serum total bilirubin levels were not signiﬁcantly different in
the 2 groups. In a larger retrospective study, Cantoni et al. [15]
reported lower rates of SOS and transplantation-related
mortality in a cohort of 59 patients conditioned with CY/BU
compared with a small historical cohort of 16 patients condi-
tioned with BU/CY.
Our results extend the previous retrospective reports in
the form of a prospective clinical trial. In addition to
prospective enrollment, novel aspects of the present study
include a focus on patients at high risk for hepatotoxicity (ie,
those with myeloﬁbrosis), the availability of a large cohort of
concurrent control patients conditioned with TBU/CY, the
determination of CY pharmacokinetics, and pharmacokinetic
BU targeting to rule out variability in BU exposure as a con-
founding factor. The target plasmaBUCsswas 800-900ng/mL
for 100% of the cases (i.v. BU) and 96.7% of the controls (oral
and i.v. BU). Intravenous BUhas been associatedwith reduced
hepatotoxicity compared with oral BU when dosed by body
weight [33]. However, when BU dosing is personalized to
a target steady-state concentration, as in the present study,
outcomes appear to be similar regardless of administration
route [26]. Thus, given the consistent pharmacokinetictargeting of BU in our case and control patients, the route of
administration is unlikely to account for the observed
differences in outcomes.
We found a greater risk of relapse in patients with AML/
MDS conditioned with CY/TBU compared with those condi-
tioned with TBU/CY. Some of this risk may be related to
confounding variables; patients at high baseline risk of
relapse were over-represented in the case cohort, and the
relapse rate in the control cohort (20%) was somewhat lower
than that generally reported in the literature [34]. None-
theless, we cannot rule out the possibility that reversing the
sequence of conditioning agents may increase the risk of
relapse in patients with AML/MDS. Thus, our data do not
support the use of this regimen to treat AML/MDS outside
the conﬁnes of a well-designed clinical trial.
The major limitation of the present study is our use of
a concurrent/historical control cohort rather than prospec-
tive randomization between the CY/TBU and TBU/CY arms.
Our control cohort contained a higher proportion of patients
receiving bone marrow (as opposed to G-PBMC) allografts.
However, given that the most recent available data suggest
equivalent outcomes with bone marrow and G-PBMC allo-
grafts [35], this discrepancy is unlikely to be a signiﬁcant
source of bias in terms of the clinical outcomes of interest.
Similarly, our control cohort contained a larger number of
patients with HLA-mismatched donors compared with our
case cohort. However, after excluding patients with HLA-
mismatched donors from both cohorts, CY/TBU condi-
tioning continued to be associated with a signiﬁcantly lower
incidence of SOS (0% versus 28%; P¼ .01) and lower dayþ100
mortality (2% versus 12%; P ¼ .02) in patients with myeloﬁ-
brosis, suggesting that our ﬁndings were not inﬂuenced by
this imbalance in donorerecipient HLA matching.
In conclusion, ourdata indicate that reversing the sequence
of conditioning agents from TBU/CY to CY/TBU before alloge-
neic HCT is associated with reduced day þ100 mortality and
a decreased incidence of SOS in patients with myeloﬁbrosis.
This reduced hepatotoxicity was likely mediated by reduced
A.R. Rezvani et al. / Biol Blood Marrow Transplant 19 (2013) 1033e1039 1039exposure to toxic CYmetabolites. This change in conditioning
sequence, which requires no additional institutional expertise
and uses existing medications and technology, can substan-
tially reduce regimen-related toxicity and early mortality and
improve outcomes in patients undergoing allogeneic HCT for
myeloﬁbrosis.
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